NCT05526300Completed
Intelligent Hypertension Intervention Study
Randomized Study of Antihypertensive Intervention by Intelligent Hypertension Management System
Source: ClinicalTrials.gov · Last updated 21 May 2025
Brief summary (registry, in English)
To explore whether the application of intelligent hypertension management system can effectively reduce blood pressure in hypertensive patients. A total of 320 eligible subjects will be recruited and randomization to two groups. The standard care group (n=160) will receive conventional hypertension treatment with baseline data collected.Wearable blood pressure monitoring device management group (intervention group, n=160) will receive blood pressure monitoring remotely everyday and antihypertension medication treatment. Primary outcome is Net change in systolic blood pressure from baseline to 3 months follow-up. Secondary outcomes include Net change in diastolic blood pressure hypertension control ratio (BP \< 140/90 mmHg)
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 320 (actual)
- First submitted
- 31 Aug 2022
- Start date
- 6 Sept 2022
- Primary completion date
- 1 Dec 2024
- Lead sponsor
- Shanghai Tong Ren Hospital
- Diseases
- High blood pressure
- NCT number
- NCT05526300
What you commit to
- Study type: Interventional
- Participants enrolled: 320
- From 6 Sept 2022 to the primary completion date, 1 Dec 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with secondary hypertension
- Known active malignancy disease
Lab values
- Severe hepatic and renal insufficiency (ALT \> 5 times ULA, eGFR \< 15ml/min/1.73mm2)
Other
- Pregnant women or women planning to become pregnant within the next year;
- Patients with life expectancy less than 1 year
- The researcher believes that patients who are not suitable to participate in this study
Who the study is looking for
- Aged more than 18 years old, less than or equal to 75 years old.
- Hypertensive patients (systolic/diastolic blood pressure ≥140/90 mmHg at two separate screening/baseline visits)
- Patients or guardians can skillfully use devices such as smartphones and electronic sphygmomanometers
- Voluntarily joined and signed the informed consent
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Songjiang hospital, Shanghai jiaotong University, School of medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Shanghai Fifth Rehabilitation Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Shanghai Tongren Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.